TrianglePUBLICATIONS · 17018856
Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Blood
- Publication date
- 2007 Feb 1
- First author
- Dann EJ
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Dann EJ
- type
- Author
- name
- Bar-Shalom R
- type
- Author
- name
- Tamir A
- type
- Author
- name
- Haim N
- type
- Author
- name
- Ben-Shachar M
- type
- Author
- name
- Avivi I
- type
- Author
- name
- Zuckerman T
- type
- Author
- name
- Kirschbaum M
- type
- Author
- name
- Goor O
- type
- Author
- name
- Libster D
- type
- Author
- name
- Rowe JM
- type
- Author
- name
- Epelbaum R
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Dann EJ
- type
- Author
- name
- Bar-Shalom R
- type
- Author
- name
- Tamir A
- type
- Author
- name
- Haim N
- type
- Author
- name
- Ben-Shachar M
- type
- Author
- name
- Avivi I
- type
- Author
- name
- Zuckerman T
- type
- Author
- name
- Kirschbaum M
- type
- Author
- name
- Goor O
- type
- Author
- name
- Libster D
- type
- Author
- name
- Rowe JM
- type
- Author
- name
- Epelbaum R
- type
- Author
- bibliography ids
- nci-bib-4fa293b6c9db991106b51d97
- book metadata
- content sha256
- c23b4adba1f86bc5506332116b0ba6c0c4cefbe6ff1e489beb8044c1643fbb61
- document type
- citation
- dois
- 10.1182/blood-2006-04-019901
- electronic publication date
- display
- 2006 Oct 3
- precision
- day
- year
- 2006
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:17018856
- immutable id
- pubmed:17018856@c23b4adba1f86bc5506332116b0ba6c0c4cefbe6ff1e489beb8044c1643fbb61
- journal
- abbreviation
- Blood
- issn electronic
- Source null
- issn print
- 0006-4971
- issue
- 3
- name
- Blood
- nlm unique id
- 7603509
- pages
- 905-9
- volume
- 109
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 17018856
- provenance
- batch id
- 2c499a3b9f4867a74c49
- provider
- NCBI PubMed ESummary
- record sha256
- ec05521a8af62360213c95ddb9392a19a5387bb65dcef22a5de4507ece5ade82
- response sha256
- 3b299651c5c5270455877b65b6e5acff71ad5f85103b7f9582efe63c52588326
- retrieved at
- 2026-09-09T23:46:08.887541+00:00
- publication date
- display
- 2007 Feb 1
- precision
- day
- year
- 2007
- publication types
- Clinical Trial
- Journal Article
- Multicenter Study
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome.
Preserved source evidence · Not medical advice